Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Juliana Borges Vieira"'
Autor:
Luisa Helena Andrade da Silva, Juliana Borges Vieira, Marianna Ribeiro Cabral, Mariana Alves Antunes, Daiheon Lee, Fernanda Ferreira Cruz, Justin Hanes, Patricia Rieken Macedo Rocco, Marcelo Marcos Morales, Jung Soo Suk
Publikováno v:
Bioengineering & Translational Medicine, Vol 8, Iss 2, Pp n/a-n/a (2023)
Abstract Silicosis is an irreversible and progressive fibrotic lung disease caused by massive inhalation of crystalline silica dust at workplaces, affecting millions of industrial workers worldwide. A tyrosine kinase inhibitor, nintedanib (NTB), has
Externí odkaz:
https://doaj.org/article/0991f56d77644bf8a48ac09618c14e7b
Autor:
Luisa Helena Andrade da Silva, Juliana Borges Vieira, Marianna Ribeiro Cabral, Mariana Alves Antunes, Daiheon Lee, Fernanda Ferreira Cruz, Justin Hanes, Patricia Rieken Macedo Rocco, Marcelo Marcos Morales, Jung Soo Suk
Publikováno v:
Bioengineering & Translational Medicine. 8
Autor:
null Luisa Helena Andrade da Silva, null Juliana Borges Vieira, null Marianna Ribeiro Cabral, null Mariana Alves Antunes, null Daiheon Lee, null Fernanda Ferreira Cruz, null Justin Hanes, null Patricia Rieken Macedo Rocco, null Marcelo Marcos Morales, null Jung Soo Suk
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::710778730d20cae26233fc7399f62121
https://doi.org/10.1002/btm2.10401/v2/response1
https://doi.org/10.1002/btm2.10401/v2/response1
Autor:
Juliana Borges Vieira, Rebecca Madureira Bose, Patricia R. M. Rocco, Douglas E. Teixeira, Rodrigo P. Silva-Aguiar, Fernanda F. Cruz, Cassia L. Braga, Celso Caruso-Neves, Nathane S. Felix, Nazareth N. Rocha, Mariana A. Antunes, Pedro L. Silva
Publikováno v:
European journal of pharmacology. 887
Despite advances in medical therapy, pulmonary arterial hypertension (PAH) remains an inexorably progressive and highly lethal disease. Signal transducer and activator of transcription (STAT)-3 is one of the main intracellular transcription factors i
Autor:
Patricia R. M. Rocco, Lucas de Mendonça, Cynthia S. Samary, Nathane S. Felix, Juliana Borges Vieira, Cassia L. Braga, Pedro L. Silva, Fernanda F. Cruz, Gisele Zapata-Sudo, Jaqueline S da Silva, Nazareth N. Rocha
Publikováno v:
Br J Pharmacol
Background and purpose Pulmonary arterial hypertension (PAH) is a progressive disease associated with high morbidity and mortality, despite advances in medical therapy. We compared the effects of infigratinib (NVP-BGJ398), a new FGF receptor-1 inhibi